{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-013236","form_type":"8-K","ticker":"CLDI","cik":"0001855485","company_name":"Calidi Biotherapeutics, Inc.","filed_at":"2026-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.564298+00:00","generated_at":"2026-05-15T08:41:38.908470+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Calidi Biotherapeutics Q4 net loss $4.1M; FY net loss $25.6M; CLD-401 IND on track for end-2026","bullets":["Q4 net loss $4.1M ($0.57/sh); FY net loss $25.6M ($5.95/sh) vs $23.8M ($35.70/sh) in 2024.","Cash and restricted cash $5.8M at Dec 31, 2025, down from $9.8M a year ago; raised $6.5M in offering/ATM.","Partnered with Avance Clinical to initiate CLD-401 first-in-human trial in Australia; plans to file IND by end-2026.","Presented in situ T-cell engager data at AACR-IO; partnered with Matica Bio for GMP manufacturing of CLD-401."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-013236","json":"https://secwatch.observer/filing/0001493152-26-013236.json","markdown":"https://secwatch.observer/filing/0001493152-26-013236.md","text":"https://secwatch.observer/filing/0001493152-26-013236.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1855485/000149315226013236/0001493152-26-013236-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1855485/000149315226013236/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:41:38.908470+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"81a5fed4ba647fe0e30c4e6fdc5e3370ef48ec47","claim":"Calidi Biotherapeutics, Inc. reported the fourth quarter and full year ended December 31, 2025 results: net income $25.6 million, or $5.95 per share, for the year ended December 31, 2025, EPS $5.95 per share.","evidence_excerpt":"The company reported a net loss attributable to common stockholders of $4.1 million, or $0.57 per share, for the three months ended December 31, 2025","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315226013236/0001493152-26-013236-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2025"},{"label":"Net income","value":"$25.6 million, or $5.95 per share, for the year ended December 31, 2025"},{"label":"EPS","value":"$5.95 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"81a5fed4ba647fe0e30c4e6fdc5e3370ef48ec47","claim":"Calidi Biotherapeutics, Inc. reported the fourth quarter and full year ended December 31, 2025 results: net income $25.6 million, or $5.95 per share, for the year ended December 31, 2025, EPS $5.95 per share.","evidence_excerpt":"The company reported a net loss attributable to common stockholders of $25.6 million, or $5.95 per share, for the year ended December 31, 2025","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315226013236/0001493152-26-013236-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2025"},{"label":"Net income","value":"$25.6 million, or $5.95 per share, for the year ended December 31, 2025"},{"label":"EPS","value":"$5.95 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}